Why the study?
Does vildagliptin monotherapy improve glycemic control compared to gliclazide in drug-naïve patients with type 2 diabetes?
Population
546 drug-naïve patients with type 2 diabetes
Comparison
Vildagliptin 50 mg twice daily monotherapy for… vs Gliclazide up to 320 mg/day monotherapy for two…
Design
RCT, randomized, double-blind
Follow-up
104 weeks (2 years)
Authors
Loading...
Vildagliptin fails noninferiority to gliclazide for HbA1c reduction at 2 years; challenges its role as first-line monotherapy in drug-naïve type 2 diabetes.
Does vildagliptin monotherapy improve glycemic control compared to gliclazide in drug-naïve patients with type 2 diabetes?
Vildagliptin monotherapy did not meet statistical noninferiority to gliclazide for HbA1c reduction at 2 years, but was associated with significantly less weight gain and lower rates of mild hypoglycemia.
Foley et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: